Shares of Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.77 and traded as high as $2.01. Fortress Biotech shares last traded at $1.89, with a volume of 437,565 shares.
Fortress Biotech Stock Down 5.0%
The business's fifty day moving average is $1.84 and its two-hundred day moving average is $1.77. The company has a market cap of $55.89 million, a P/E ratio of -0.85 and a beta of 1.75. The company has a debt-to-equity ratio of 1.74, a quick ratio of 1.55 and a current ratio of 1.72.
Institutional Investors Weigh In On Fortress Biotech
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HB Wealth Management LLC lifted its holdings in Fortress Biotech by 6.1% during the 1st quarter. HB Wealth Management LLC now owns 113,350 shares of the biopharmaceutical company's stock valued at $177,000 after buying an additional 6,500 shares in the last quarter. PFG Investments LLC lifted its holdings in Fortress Biotech by 28.4% during the 1st quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 10,000 shares in the last quarter. Wolverine Trading LLC bought a new stake in Fortress Biotech during the 4th quarter valued at about $26,000. PVG Asset Management Corp lifted its holdings in Fortress Biotech by 3.3% during the 4th quarter. PVG Asset Management Corp now owns 386,295 shares of the biopharmaceutical company's stock valued at $782,000 after buying an additional 12,505 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its holdings in Fortress Biotech by 28.9% during the 4th quarter. Integrated Wealth Concepts LLC now owns 59,400 shares of the biopharmaceutical company's stock valued at $120,000 after buying an additional 13,300 shares in the last quarter. Institutional investors own 96.51% of the company's stock.
About Fortress Biotech
(
Get Free Report)
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
Featured Articles
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
